New 24-Month Data Shows Nevro’s SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep REDWOOD CITY, Calif., Aug. 16, 2023 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company delivering…

Click here to view original post